



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23L 1/29	A1	(11) International Publication Number: WO 99/01044 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US98/11986 (22) International Filing Date: 10 June 1998 (10.06.98) (30) Priority Data: 08/887,001 2 July 1997 (02.07.97) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: AGOSTA, Phyllis, J., B.; 1287 Gemstone Square West, Westerville, OH 43081 (US). BORSCHER, Mar- lene, W.; 340 East North Street, Worthington, OH 43085 (US). REYNOLDS, Patricia, A.; 5700 Jousting Lane, Columbus, OH 43231 (US). CORDLE, Christopher, T.; 92 South Preston Street, Centerburg, OH 43011-0016 (US). DUSKA-McEVEN, GERALYN, O.; 336 Spruce Hill Drive, Gahanna, OH 43230 (US). (74) Agents: DIXON, J., Michael; Abbott Laboratories, Ross Products Division, Dept. 108140/DS-1, 625 Cleveland Avenue, Columbus, OH 43215-1724 (US) et al.		(81) Designated States: CA, JP, MX, NO, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: PALATABLE ELEMENTAL MEDICAL FOOD		
(57) Abstract <p>This invention relates to a palatable elemental nutritional formula that is nutritionally complete for humans with specialized dietary needs. The nutritional of the present invention uses specific free amino acids to provide the source of amino nitrogen (protein equivalents) and a special blend of fats that provides 38 to 50 % of the total calories in a pleasant tasting formula. The nutritionally complete formula of this invention is useful for children having multiple protein allergies, short gut syndrome, sick gut, diarrhea and the like. More specifically, the nutritional product, in accordance with this invention, utilizes L-asparagine monohydrochloride and L-glutamine in place of L-aspartic acid and L-glutamic acid, respectively. In addition, the source of fat comprises soy, fractionated coconut oil (medium chain triglycerides), high oleic safflower oil and esterified glycerol emulsifiers. The level of fat calories is about 38 to 50 % of total calories, which produces a product having a low osmolarity and provides required energy requirements in a small volume.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PALATABLE ELEMENTAL MEDICAL FOOD**Field of the Invention**

This invention relates to improved enteral nutritional hypoallergenic formulas and more particularly to hypoallergenic formulas that taste good. In addition, the nutritional product of this invention provides a nutritionally complete hypoallergenic food for individuals with multiple food allergies, short gut syndrome, cystic fibrosis, pancreatic disease, gastroenteritis, inflammatory bowel disease, intractable diarrhea, malnutrition, protein maldigestion, infectious diseases or for patients with hypermetabolism, such as burn and trauma victims or cancer patients.

Background of the Invention

Hypoallergenic formulas or compositions that are also referred to as elemental formulas, are characterized in that they contain immunologically unreactive protein hydrolysates or free amino acids. The protein hydrolysates comprise short peptide fragments and/or free amino acids instead of the intact protein found, for example, in cow's milk and soy protein based formulas. These short peptide fragments and free amino acids have been found to be less immunogenic or allergenic than intact proteins.

In addition to the protein hydrolysates and/or free amino acids, most nutritionally balanced elemental or hypoallergenic formulas contain carbohydrates, lipids, vitamins and minerals to provide a nutritionally complete formula. These formulas are utilized for feeding infants, children and adults who have allergies or sensitivities to intact protein and are often medically used in the treatment of cystic fibrosis, chronic diarrhea, small bowel resection, steatorrhea and protein-calorie malnutrition.

One well known problem in the preparation of elemental or hypoallergenic formulas is product instability. Extensive hydrolysis of the protein by acids, or enzymes is necessary to provide the short peptides and amino acids utilized in the formulas to render such formulas hypoallergenic. These extensively digested proteins or free amino acids have undesirable characteristics such as bad taste and loss of capacity to emulsify fat and thereby fail to form physically stable emulsions that do not evidence phase separation.

U.S. Patent No. 4,414,238 to Schmidl, et al., discloses an elemental diet composition comprising carbohydrates, amino acids and/or low molecular weight peptides and lipids. The elemental diet of this patent has a lipid component in the form of an emulsion consisting of lipids, an

emulsifier selected from the group consisting of mono- and di-glycerides, and a starch modified with succinic anhydride.

U.S. Patent No. 4,670,268 to Mahmoud discloses an enteral nutritional hypoallergenic formula that uses a starch modified by octenyl succinic anhydride, that is utilized as the sole lipid
5 emulsifier, to provide a nutritionally well-balanced dietary formula that possesses excellent physical stability.

U.S. Patent No. 5,411,751 to Crissinger discloses infant formulas that contain no more than subirritant levels of free, long-chain (C_{16} - C_{22}) fatty acids and triglycerides thereof. This patent teaches that digestion products of triglycerides, in particular, long-chain fatty acids and
10 monoglycerides, can damage the intestinal epithelium of infants and could mediate the onset of disorders such as necrotizing enterocolitis. This patent does not suggest or disclose a palatable elemental or hypoallergenic medical food that is essentially free of L-glutamic acid and L-aspartic acid.

U.S. Patent No. 5,234,702 to Katz, et al., discloses a powdered nutritional product that uses
15 an antioxidant system to protect the oil component comprising ascorbyl palmitate, beta carotene and/or mixed tocopherols and citrate. The teachings of this patent are incorporated herein by reference.

U.S. Patent No. Re. 35,233, discloses a method of treating atrophy of skeletal muscle and intestinal mucosa that comprises enterally administering glutamine or a functional derivative thereof
20 in the range of 0.4 to 3.0 g/kg/day.

The nutritional formula according to this invention has been carefully formulated to provide a nutritional product that can be the sole source of nutrition for patients consuming it. To provide effective nutrition to human infants, children and adults, the present invention, in its most specific embodiments, carefully considers the bioavailability of trace and ultratrace minerals and the dietary
25 interactions involving trace elements. Therefore, the teachings of Forbes, et al., *Bioavailability of Trace Mineral Elements*, Ann. Rev. Nutr. 1983, 3:213-231 and Mills, *Dietary Interactions Involving the Trace Elements*, Ann. Rev. Nutr. 1985, 5:173-193, are incorporated herein by reference.

U.S. Patent Nos. 5,326,569 and 5,550,146 to Acosta, et al., disclose a generic powder base, rich in fats, carbohydrates, vitamins, minerals and trace elements that are admixed with
30 specific amino acids to yield several different therapeutic products that are used in the nutritional support of adults and children having various inherited metabolic diseases. These patents do not suggest or disclose the nutritionally complete hypoallergenic formulas of this invention that are essentially free of L-glutamic acid and L-aspartic acid.

The etiology of a number of gastrointestinal conditions has been demonstrated to be caused in some cases by food protein allergens. One such gastrointestinal condition is eosinophilic gastroenteritis. Eosinophilic gastroenteritis is characterized by peripheral eosinophilia, eosinophilic infiltration of the bowel wall, and various gastrointestinal symptoms. In pediatric cases, food antigens are the most common cause of eosinophilic gastroenteritis. Administration of an elemental, hypoallergenic diet may be required for rapid recovery as even extensively hydrolyzed casein-based formulas such as Alimentum® Protein Hydrolysate Formula With Iron (Ross Products Division, Abbott Laboratories, Columbus, Ohio) contains peptide fragments large enough to evoke an allergic reaction in the most sensitive of allergic individuals.

U.S. Patent No. 5,492,899 to Masor, et al., discloses an enteral nutritional formula containing ribonucleotides at specified levels. The formula of this patent comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) specified nucleotides at specific levels and ratios. One preferred embodiment of the present invention includes the presence of nucleotides in the elemental hypoallergenic medical food. The teachings of U.S. Patent 5,492,899 are incorporated herein by reference.

U.S. Patent No. 5,340,603 to Neylan, et al., relates to a hypercaloric formula that provides nutritional support for human infants having chronic lung disease. The formula of this patent has a Caloric density of at least 800 kcal per liter of formula and wherein not less than 56% of the total Calories in said formula is derived from fat. In addition, the hypercaloric formula of this reference contains not more than 15% of total Calories derived from a high quality protein source and from about 20 to 27% of total Calories from a carbohydrate source. The formula of this patent also includes m-inositol at a concentration of at least 50 mg per liter of formula.

U.S. Patent 5,411,757 to Buist, et al., relates to a balanced, palatable medical diet for treatment of patients with inborn errors of essential amino acid metabolism. The diet of this patent uses L-amino acids at specified weights and ratios. More specifically, this patent discloses a palatable medical diet wherein the protein equivalent of L-amino acids is formed by the acetylation or the esterification of the L-amino acids. In contrast, the present invention uses L-amino acids to supply the amino nitrogen (protein equivalent) except for the replacement of L-asparagine for aspartic acid and L-glutamine for glutamic acid.

A presently available product known as Vivonex® Pediatric is marketed by the Clinical Products Division of Sandoz Nutrition, Minneapolis, Minnesota for the gastrointestinally impaired child. The Vivonex® Pediatric contains 100% free amino acids and has an osmolality at standard

dilution of 1 kcal/ml of 490 mOsm/kg H₂O. This product derives 25% of total Calories from fat with 68% of those Calories from medium chain triglycerides.

Neocate® One + marketed by Scientific Hospital Supplies, Inc. (SHS) North America, Gaithersburg, Maryland, is a pediatric elemental nutritional that is marketed in liquid and powdered forms and is designed for children over one year of age. This liquid product contains 100% of its amino nitrogen in the form of free L-amino acids and has an osmolality at standard dilution (100 kcal/100 ml) of 835 mOsm/kg H₂O. Neocate® One + powder (unflavored), when mixed to yield 100 kcal/100 mL, has an osmolality of 610 mOsm/kg H₂O. These products contain 3.5 grams of fat per 100 mL at a Caloric density of 100 kcal/100 mL. Neocate®, also marketed by SHS in the U.K., Scandinavia and the USA, uses maltodextrin as the carbohydrate source, contains 11.4% of Calories from free L-amino acids and 44.3% of Calories from fat wherein the fat is a mixture of refined lard, peanut oil and coconut oil.

In general, the prior art elemental or hypoallergenic formulas suffer from poor taste (organoleptic properties), high osmolality and low Caloric density. In contrast, the present invention has acceptable organoleptic properties thereby facilitating oral consumption by the patient that also increases patient compliance with diet restrictions. The improved organoleptic properties are accomplished in part, by essentially excluding L-glutamic acid and L-aspartic acid from the formula and replacing them with L-glutamine and L-asparagine monohydrate. Further, the present invention is differentiated from the prior art in that it contains a higher Caloric content from fat that assists in improving organoleptic properties; reduces osmolality and increases overall Caloric density. Further, the specific fat blend of the invention provides a balance of the essential fatty acids linoleic and α-linolenic, in a readily absorbable form.

Summary of the Invention

The present invention relates to an improved elemental formula comprising carbohydrates, lipids, free L-amino acids, vitamins and minerals. The invention is based, in part, on the discovery that the use of medium chain triglycerides (MCT's) or fractionated coconut oil, soy oil, esterified glycerol emulsifiers and high oleic safflower oil as the lipid component, in combination with the use of L-asparagine monohydrate in place of L-aspartic acid and L-glutamine in place of L-glutamic acid, vastly improves the organoleptic properties of the hypoallergenic formula. The present invention also uses a high level of fat to result in a product having a low osmolality and also provides needed energy requirements in a small volume.

One aspect of the present invention relates to the preparation of an elemental medical food that is essentially free of L-glutamic acid and L-aspartic acid. In the present invention, L-glutamic acid ($C_5H_9NO_4$, mol. wt. 147.13) is replaced with L-glutamine ($C_5H_{10}N_2O_3$, mol. wt. 146.15), the monoamide of glutamic acid and L-aspartic acid ($C_4H_7NO_4$, mol. wt. 133.10) is replaced with

5 L-asparagine monohydrate ($C_4H_8N_2O_3 \cdot H_2O$, mol. wt. 150.13), the monoamide of aspartic acid with one molecule of water. As used herein and in the claims, the phrase "to be essentially free of L-glutamic acid and L-aspartic acid" means less than 5 mgs of each acid should be present in 100 gms of powdered product (less than 50 ppm).

The present invention also relates to a complete pediatric hypoallergenic formula suitable for

10 feeding to children on allergen-free diets. The formula according to this invention uses free L-amino acids as the source of amino nitrogen and meets the recommended dietary allowances (RDA) for the 1 to 3 year old child in 1000 kcal and for the 4 to 6 year old child in 1500 kcal. As used herein and in the claims, the term "protein equivalent" means the amount of amino nitrogen in grams present in the formulation multiplied by 6.25.

15 There is disclosed an elemental medical food for administration to a human comprising a) a carbohydrate component that comprises from 38-56% of the total Caloric content of said food; b) a lipid component that comprises from 38-50% of the total Caloric content of said food and wherein said lipid component is a blend of high-oleic safflower oil, fractionated coconut oil (medium chain triglycerides), soy oil and esterified glycerols; and c) an amino acid component that comprises from

20 10-20% of the total Caloric content of said food and wherein the amino acid component is essentially free (less than 5 mgs per 100 gms of powdered product) of L-glutamic acid and L-aspartic acid. The term "essentially free" means each of the amino acids are at concentrations of less than 5 mgs per 100 gms (50 ppm) of powdered product.

There is also disclosed a method for providing nutrition support to a human suffering from a

25 malady selected from the group consisting of multiple food allergies, short gut syndrome, cystic fibrosis, pancreatic disease, gastroenteritis, inflammatory bowel disease, intractable diarrhea, malnutrition, protein maldigestion, infectious diseases such as HIV, hypermetabolism, trauma, eosinophilic gastroenteritis and gastroesophageal reflux; said method comprises administering to said human a hypoallergenic formula in accordance with the present invention.

30 More specifically, this invention relates to an elemental medical food and method of its use wherein the carbohydrate component comprises from 38 to 56% of the total Caloric content of the composition and wherein the lipid component comprises from 38 to 50% of the total Caloric content of the composition and wherein the amino acid or protein equivalent component comprises from 10

to 20% of the total Caloric content of the composition. In a more preferred embodiment, the lipid component comprises 38-46% of the total Caloric content of the composition. The lipid component of this invention supplies 2-8% by wt. of the powdered product as linoleic acid (5-15% of Calories) and 0.4 to 1.0% by wt. of the powdered product as α -linolenic acid (0.8-2% of total Calories).

5 Preferably, the carbohydrate component of this invention consists essentially of corn syrup solids at a dextrose equivalent (DE) of 23 or less.

A stabilizer system is used in the formula of this invention and can be a single component or a mixture of known stabilizers. As mentioned previously, a major challenge in developing an elemental nutritional is physical stability. Physical stability relates to the oil and water emulsion of the formula. Those skilled in the art understand that free amino acids and hydrolyzed proteins do not produce emulsions that are stable over time. It is important that the elemental medical foods of this invention possess acceptable physical stability as separation of the emulsion into water and oil phases greatly decreases the palatability of the formula and may result in inadequate nutrition.

The inventors herein have evaluated numerous emulsion stabilizers and have determined that esterified glycerol emulsifiers such as diacetyl tartaric esters of monoglycerides are very useful in the present invention. Diacetyl tartaric acid esters of monoglycerides (hereinafter "DATEM") are commercially available and generally regarded as safe for human consumption by the USFDA. Representative DATEM emulsion stabilizers useful in the present invention include the Panodan® line of emulsion stabilizers sold by Grinsted Products, Inc. of Kansas, U.S.A. Panodan® is made from edible refined vegetable fat.

In one embodiment of the present invention, the DATEM emulsion stabilizer is the sole emulsion stabilizer and is present in the elemental medical food of this invention at a level of up to 8% by weight of the lipid. DATEM is grouped in the lipid component since upon ingestion, esterases cleave the fatty acid moiety from the tartaric acid moiety. The fatty acid then is absorbed and metabolized while the tartaric acid clears the body un-metabolized. The profile of Panodan® emulsion stabilizer sold by Grinsted is as follows:

	Component	
	<u>Fatty Acid</u>	<u>Wt %</u>
30	14:0	0.1
	16:0	6.6
	18:0	54.5
	18:1	0.3
	20:0	0.4
35	Diacetyl tartaric Acid	38.1

Another important aspect of the present invention relates to the use of an antioxidant system to lessen oxidation of the lipid component. Those skilled in this art will appreciate that the use of unsaturated oils in a powdered elemental product present special problems. To overcome the oxidation (spoilage) of the oils in the powdered product, the present invention, in one preferred
5 embodiment, uses an anti-oxidant system comprising ascorbyl palmitate, beta carotene and citrate. The teachings of U.S. Patent 5,234,702 to Katz, et al., entitled ANTIOXIDANT SYSTEM FOR POWDERED NUTRITIONAL PRODUCTS, are incorporated herein by reference.

Detailed Description of the Invention

10 All of the components of the inventive formulation are commercially available from numerous sources. For example, the carbohydrate source that is preferably corn syrup solids with a DE of less than 23 is available from Grain Processing Corporation, Muscatine, IA. The amino acids are available from Kyowa Hakko, Ajinomoto and Tanabe of Japan, and Degussa of Germany. The lipids are available from Stepan Co., Maywood, N.J. and California Oils, Richmond, CA. The L-glutamine
15 component is available from Kyowa Hakko of Japan and the L-asparagine monohydrate is available from Degussa.

In accordance with this invention, the osmolality of the formula can range from 300 to 400 mOsm/kg H₂O, and more preferably from 350 to 375 mOsm/kg H₂O when 4.2 g of said powdered composition is added to water to yield 29.57 ml of formula. As one skilled in this art will appreciate,
20 the osmolality of the formula will vary with the concentration or Caloric density of the formula. For example, at a Caloric density of 68 kcal/100 ml, the osmolality of the RTF (ready-to-feed) formula can range from 350-375 mOsm/kg H₂O. At a Caloric density of 135 kcal/100 ml, the osmolality of the formula can range from 850-900 mOsm/kg H₂O.

One aspect of the present invention resides in the use of corn syrup solids for the
25 carbohydrate source. It is important to use a source of carbohydrate that will not adversely affect (increase to a high value) the osmolality of the final product particularly when L-amino acids supply the protein equivalent, since they are small molecules that add considerably to osmolality. Those skilled in the art will appreciate that high osmolalities (i.e., above about 450 mOsm/kg H₂O for infants and about 750 mOsm/kg H₂O for children) in a liquid nutrition product can cause gastric upset and
30 diarrhea. Therefore, the use of types of carbohydrates, such as dextrose and sucrose, that would increase the osmolality above about 400 mOsm/kg H₂O for infants, and about 750 mOsm/kg H₂O for children is discouraged. In a preferred embodiment, the carbohydrate used in the present invention

has a DE (dextrose equivalent) of no more than 23 and is corn syrup solids. Use of a carbohydrate with a DE of greater than 23 in combination with L-amino acids will provide an osmotic pressure in the intestine that may lead to bloating, diarrhea and dehydration. These are conditions that should be avoided in patients already suffering from gastrointestinal problems. The medical food in accordance with this invention provides a good balance of Caloric density and acceptable osmolality. As those skilled in this art will appreciate, as the DE of the carbohydrate increases, the osmolality of the formula will also increase. The preferred source of carbohydrate is corn syrup solids with a DE of 23 or less.

Also contemplated in this invention is an elemental medical food that is flavored. Flavorings and sweeteners (preferably not sucrose or glucose) known in the food industry are acceptable provided the consuming patients are not allergic thereto and the osmolality of the final product is acceptable. A vanilla flavored product sweetened with the artificial sweetener aspartame (NutraSweet®) was produced based on Example I. The osmolality of the flavored product at 68 kcal/100 ml was 370 mOsm/kg H₂O and 895 mOsm/kg H₂O at 135 kcal/100 ml.

There is also disclosed a lipid component for use in the present invention that comprises on a weight percent of the lipid component, 35 to 43% high oleic safflower oil, 28 to 35% fractionated coconut oil (MCT's), 24 to 30% soy oil, and 0.5 to 8% esterified glycerols. In the lipid component of this invention, the level of linoleic acid may range from 15 to 22% and the level of α -linolenic may range from 2 to 5% by weight of the total lipid component.

A representative blend of 6.4 gms of soy oil, 9.0 gms of high oleic safflower oil, 7.6 gms of fractionated coconut oil and 1.4 gms of DATEM were incorporated into the elemental medical food according to this invention and then analyzed for fatty acid content. Table I sets forth the name of the fatty acid, gms of fatty acid per 100 gms powder, % of energy and weight % of fat.

TABLE I

NAME	NO. OF CARBONS	G/100 G ¹ POWDER	% OF ENERGY	% OF FAT WT.
Caproic	C6:0	0.068	0.129	0.29
Caprylic	C8:0	4.230	8.015	18.00
Capric	C10:0	3.032	5.745	12.90
Lauric	C12:0	0.042	0.080	0.18
Palmitic	C16:0	1.191	2.257	5.07
Palmitoleic	C16:1n7	0.014	0.027	0.06
Stearic	C18:0	1.159	2.196	4.93
Oleic	C18:1n9	8.342	15.806	35.50
Linoleic	C18:2n6	4.653	8.816	19.80
α -Linolenic	C18:3n3	0.531	1.006	2.26
Arachidic	C20:0	0.067	0.127	0.29
Eicosenoic	C20:1n9	0.046	0.087	0.19
Behenic	C22:0	0.051	0.097	0.22
Lignoceric	C24:0	0.024	0.045	0.10
Nervonic	C24:1n9	<u>0.018</u>	<u>0.034</u>	<u>0.08</u>
TOTALS		23.468	44.467	99.87
Monounsaturated fatty acids		8.420	15.954	35.83
Polyunsaturated fatty acids		5.184	9.822	22.06
Saturated fatty acids		9.864	18.690	41.97

¹ Analytical data

5 On analysis, one cannot differentiate the fatty acids from Panodan, soy oil and HO safflower oil.

In a further embodiment of the present invention, there is disclosed a powdered, elemental medical food that comprises per 100 g of powder further described in Table II.

TABLE II
Elemental Medical Food
Range Per 100 g Product

Nitrogen, g	2.32 - 2.92
Protein Equivalent, g	14.3 - 17.9
Fat, g	22.6 - 24.5
Moisture, g	1.0 - 2.0
Ash, g	3.0 - 4.5
Carbohydrate, g	46.7 - 56.0
Calories	475 - 495
Vit.A, IU	1500 - 2256
Vit.E., IU	11.6 - 15.1
Vit.D, IU	260 - 317
Vit. K, mcg	70 - 103
Pyridoxine, mg	0.57 - 0.79
Niacin, mg	9.28 - 12.47
Folic acid, mcg	177 - 282
Vit B ₁ , mg	1.42 - 1.95
Riboflavin, mg	0.62 - 0.87
Vit. B ₁₂ , mcg	4.06 - 6.46
Pantothenic acid, mg	5.05 - 8.03
Biotin, mcg	50 - 82
Vit. C, mg	200 - 400
Total Choline, mg	36 - 65
Inositol, mg	32 - 42
Calcium, mg	515 - 600
Phosphorous, mg	385 - 465
Ca/P	1.11 - 1.56
Magnesium, mg	40.0 - 60.0
Iron, mg	8.4 - 11.4
Zinc, mg	5.40 - 7.1
Manganese, mg	0.50 - 0.70
Copper, mg	0.70 - 0.90
Iodine, mcg	28 - 56
Selenium, mcg	11.0 - 20.0
Chromium, mcg	11.0 - 20.0
Molybdenum, mcg	12.0 - 26.0
Sodium, mg	217 - 257
Potassium, mg	717 - 824
Chloride, mg	285 - 395
Taurine, mg	30 - 56
L-Carnitine, mg	23 - 31

- 5 Yet more specifically, the elemental food according to this invention comprises, based on 100 kcal of said composition, 2.8 to 3.8 g of protein equivalent, 4.0 to 5.6 g of fat, 9.0 to 11.8 g of carbohydrates, 0.4 to 0.8 g linoleic acid, 262 to 475 IU Vitamin A, 40 to 80 IU Vitamin D, 2.0 to 3.5 IU Vitamin E, 5 to 20 mcg Vitamin K, 0.11 to 0.42 mg thiamine, 0.1 to 0.21 mg riboflavin, 0.09 to 0.17 mg Vitamin B-6, 0.40 to 1.36 mcg Vitamin B-12, 1.6 to 3.2 mg niacin, 28 to 60 mcg folic acid,
- 10 0.40 to 1.70 mg pantothenic acid, 4.0 to 18 mcg biotin, 8.6 to 85 mg Vitamin C, 7.5 to 14.5 mg

choline, 4.6 to 9.9 mg inositol, 4 to 6.5 mg L-carnitine, 103 to 127 mg calcium, 76 to 103 mg phosphorus, 8.0 to 12.7 mg magnesium, 1.6 to 2.4 mg iron, 1.0 to 1.7 mg zinc, 0.10 to 0.15 mg manganese, 0.11 to 0.19 mg copper, 6.7 to 11.8 mcg iodine, 2.2 to 4.7 mcg selenium, 2.2 to 4.7 mcg chromium, 2.4 to 5.5 mcg molybdenum, 40 to 55 mg sodium, 144 to 174 mg potassium and 55 to 85 mg chloride.

To convert values of nutrient per 100 kcal to values of nutrient per 100 gms of powdered product, one multiplies the 100 kcal value by 4.75.

The inclusion of nucleotides and/or nucleosides in the elemental food according to this invention is also contemplated. The teachings of U.S. Patents 5,492,899 to Masor, et al., 3,231,385 to Ziro, et al., 4,544,559 to Gil and 4,994,442 to Gil, et al., that relate to the inclusion of nucleotides in nutritional formulas, are incorporated herein by reference.

In another embodiment of the present invention, the protein equivalent component of the elemental medical food has an amino acid profile as set forth in Table III.

15

TABLE III				
Amino Acid Profile of Protein Equivalent				
	MINIMUM	MAXIMUM	MINIMUM**	MAXIMUM**
	gms/100gms*	gms/100gms*		
L-alanine	2.86	4.23	2.80	4.41
L-arginine	5.17	7.72	5.05	7.93
L-asparagine	8.37	12.42	8.35	13.10
L-cystine	1.10	1.68	1.10	1.72
L-glutamine	10.62	15.85	10.44	16.41
Glycine	2.20	3.29	2.20	3.45
L-histidine	2.20	3.29	2.14	3.38
L-isoleucine	5.72	8.53	5.60	8.83
L-leucine	9.25	13.83	9.12	14.28
L-lysine	5.17	7.66	5.05	7.93
L-methionine	2.15	3.22	2.09	3.31
L-phenylalanine	4.79	7.12	4.67	7.31
L-proline	2.92	4.16	2.80	4.41
L-serine	2.86	4.23	2.80	4.41
L-threonine	3.80	5.71	3.74	5.86
L-tryptophan	1.49	2.22	1.42	2.28
L-tyrosine	4.79	7.12	4.67	7.31
L-valine	6.55	9.74	6.43	10.07

* of amino acids

** as percent of protein equivalent

20 The Caloric density of the inventive formula is preferably from about 450 to 500 kcal/100 g of powder. The Caloric density of the RTF product can, of course, be adjusted through rate of dilution with water.

This invention relates to improved enteral nutritional hypoallergenic formulas and more particularly to hypoallergenic formulas that taste good. In addition, the nutrition product of this

invention provides a nutritionally complete hypoallergenic food for individuals with multiple food allergies, short gut syndrome, cystic fibrosis, pancreatic disease, gastroenteritis, inflammatory bowel disease, intractable diarrhea, malnutrition, protein maldigestion, infectious diseases or for patients with hypermetabolism, such as burn and trauma victims or cancer patients.

5 The present invention also relates to a method for providing nutritional support to a human suffering from gastrointestinal conditions caused by food protein allergens or severe food allergies. The method comprises the enteral administration of the hypoallergenic medical food according to this invention to a human suffering from a protein allergen induced gastrointestinal condition.

10 The elemental food according to this invention is for enteral administration and is designed to provide complete nutrition (meets all RDA's) in a small volume. For example, when the RDA for energy for age is supplied by the instant elemental food, all nutrients meet both the USFDA Infant Formula Act specifications and RDA for age in volumes noted in Table IV.

TABLE IV

<u>Age</u>	<u>Elemental Food, g</u>	<u>Add H2O to Make (mL)</u>	<u>Fl Oz</u>	<u>kcal/oz</u>
0<6 mo	137	800	27	24
6<12 mo	179	930	31	27
1<4 yr.	274	1,272	43	30
4<7 yr.	379	1,330	45	40
7<11 yr.	421	1,478	50	40

15

The following Table V is a representative listing of ingredients and a range of % by weight for each component that can be used to prepare the palatable elemental medical food of this invention.

TABLE V
Bill of Materials

	Ingredient	Per 100 lbs. powder*
5	<u>Pediatric Elemental Base</u>	
	Maltrin M200	53 lbs
	Tricalcium phosphate	1.30 lb
	Dipotassium phosphate	1.1927 lb
10	Sodium citrate	0.7451 lb
	Potassium citrate	0.9258 lb
	Magnesium chloride	0.34 lb
	Calcium carbonate	0.1702 lb
	Sodium chloride	0.036 lb
15	Potassium Iodide	0.000055 lb
	High Oleic Safflower Oil	8.9 lb
	MCT oil	7.5 lb
	Soy oil	6.4 lb
	Panodan	1.42 lb
20	Vitamin A, D3, E, K1 Concentrate	0.0338 lb
	Refined coconut oil	7.86 g
	Vitamin E acetate	6.90 g
	Vitamin A acetate	540 mg
	Phylloquinone (phytonadione)	26.1 mg
25	Vitamin D3	3.83 mg
	Ascorbyl Palmitate	0.0282 lb
	Beta Carotene	0.0009 lb
	Ascorbic Acid	0.4343 lb
	L-carnitine	0.0269 lb
30	Vitamin/Mineral/Taurine premix	0.2002 lb
	Calcium phosphate, dibasic (premix diluent)	25.4 g
	Taurine	25.0 g
	m-Inositol	18.4 g
	Zinc sulfate	7.59 g
35	Niacinamide	5.25 g
	Ferrous sulfate	2.90 g
	d-Calcium pantothenate	2.84 g
	Cupric sulfate	1.57 g
	Thiamine chloride hydrochloride	804 mg
40	Riboflavin	355 mg
	Pyridoxine hydrochloride	326 mg
	Manganese sulfate	187 mg
	Folic acid	99.9 mg
	Biotin	28.7 mg
45	Sodium selenite	14.1 mg
	Cyanocobalamin	2.29 mg
	Choline chloride	0.0584 lb
	Ferrous sulfate	0.0324 lb
	Potassium citrate	0.0020 lb
50	Manganese sulfate	0.0011 lb
	Chromium chloride	0.00005 lb
	Sodium molybdate	0.00004 lb

TABLE V (Continued)
Bill of Materials

	<u>Ingredient</u>	<u>Per 100 lbs. powder*</u>
	<u>Pediatric Elemental Base</u>	
5	<u>Amino Acid Premix:</u>	17.24 lb
	L- Glutamine	875.4 g
	L-Asparagine monohydrate	780.2 g
	L-Leucine	762.0 g
10	L-Lysine acetate	598.7 g
	L-Valine	539.8 g
	L-Isoleucine	471.7 g
	L-Arginine	426.4 g
	L-Phenylalanine	394.6 g
15	L-Tyrosine	394.6 g
	L-Threonine	313.0 g
	L-Proline	240.4 g
	L-Alanine	235.9 g
	L-Serine	235.9 g
20	Glycine	181.4 g
	L-Histidine	181.4 g
	L-Methionine	176.9 g
	L-Cystine dihydrochloride	122.5 g
	L-Tryptophan	122.5 g
25	TOTAL	99.99 lb*

*values in kilograms are set forth in Table VII

A specific embodiment of an elemental formula in accordance with the present invention is
 30 set forth in Table VI.

TABLE VI

	NUTRIENT	PER 100 G POWDER	
5	Protein Equivalent, g	14.3	
	Fat, g	22.6	
	Carbohydrate, g	46.7	
	Linoleic acid, g	2.85	
	Linolenic acid, g	0.48	
10	Calories, kcal	475	
	Calcium, mg	515	
	Phosphorus, mg	385	
	Magnesium, mg	40	
	Sodium, mEq (mg)	9.35	(215)
15	Potassium, mEq (mg)	18.29	(715)
	Chloride, mEq (mg)	8.04	(285)
	Iron, mg	8.4	
	Zinc, mg	5.3	
	Copper, mg	0.60	
20	Iodine, mcg	34	
	Manganese, mg	0.50	
	Selenium, mcg	11	
	Vitamin A, mcg RE (IU)	390	(1300)
	Vitamin D, mcg (IU)	5	(200)
25	Vitamin E, mg α -TE (IU)	6.7	(10.0)
	Vitamin K, mcg	30	
	Vitamin C, mg	43	
	Thiamin, mg	1.0	
	Riboflavin, mg	0.5	
30	Vitamin B-6, mg	0.48	
	Vitamin B ₁₂ , mcg	2.0	
	Niacin, mg	8.0	
	Folic Acid, mcg	140	
	Pantothenic Acid, mg	2.0	
35	Biotin, mcg	20	
	Choline, mg	38	
	Inositol, mg	24	
	Chromium, mcg	11	
	Molybdenum, mcg	12	
40	Taurine, mg	30	
	L-carnitine, mg	23	

The present invention will now be explained on the basis of some specific embodying examples, which, however, are to be considered as illustrative only. Unless otherwise noted, concentrations are parts by weight.

EXAMPLE 1

General Procedure

The teachings of U.S. Patent 5,326,569 to Acosta, et al., regarding the preparation of the amino acid mixtures and the process of preparing an elemental formula, are used in the preparation of the elemental formulas according to this invention and are incorporated herein by reference. An elemental formula in accordance with this invention is in general, accomplished through the dry

blending of a powdered premix base with an amino acid premix. The production of the premixed base is accomplished through the steps summarized below:

1. Preparation of Stock Solutions:
 - a. Preparation of a water soluble vitamin and trace mineral mixture;
 - b. Preparation of an ascorbic acid mixture;
 - c. Preparation of oil blend containing oil soluble vitamins; and
 - d. Preparation of a carbohydrate/mineral slurry.
2. Combination in a specified sequence of the Stock Solutions:
 - a. Mixing of the oil blend and carbohydrate/mineral slurry;
 - b. Addition of the water soluble vitamins to the slurry; and
 - c. Addition of ascorbic acid to the slurry.
3. Drying of the combined stock solutions to yield the powdered premix base.
4. Dry blending of the powdered premix base, with an amino acid premix to yield the elemental formula according to the present invention.

Commercial Scale

The clinical product utilized in Example 2 was produced on a commercial scale. A batch of 1,000 kg was produced using the method described above to insure label composition over shelf life as set forth in Table VII.

TABLE VII

INGREDIENTS	AMOUNT (kg)
MCT Oil	75.000
Soy Oil	64.000
HO Safflower Oil	89.000
Oil Soluble Vitamin Premix	0.338
Panodan	14.200
Sodium Citrate	7.451
Sodium Chloride	0.360
Potassium Citrate	9.258
Potassium Iodide	0.0005
Magnesium Chloride	0.340
Potassium Phosphate Dibasic	7.451
Calcium Carbonate	1.702
umTCP (Ultramicronized Tricalcium Phosphate)	1.300
Maltrin M200	530.
Ferrous Sulfate	0.324
Premix 1870	2.002
Manganese Sulfate	0.011
Choline Chloride	0.584
L-Carnitine	0.269
Chromium Chloride	0.005
Sodium Molybdate	0.003
Ascorbic Acid	4.343
Beta Carotene	0.009
Ascorbyl Palmitate	0.282
L-Alanine	5.70
L-Asparagine Monohydrate	19.15
Glycine	4.45
L-Arginine	10.40
L-Cystine 2-HC1	3.00
L-Glutamine	21.45
L-Histidine	4.45
L-Isoleucine	11.55
L-Lysine Acetate	14.65
L-Leucine	18.70
Phenylalanine	9.65
L-Threonine	7.70
L-Tryptophan	3.00
L-Tyrosine	9.65
L-Valine	13.20
L-Methionine	4.30
Proline	5.70
Serine	5.70
TOTAL	1000.06

5

EXAMPLE 2

A clinical study of the inventive formula was conducted at The Johns Hopkins Hospital (Baltimore, Maryland) to assess the growth, tolerance and biochemical response of children fed the formula according to the present invention as a primary feeding for four (4) months. The children, while consuming the inventive formula, were on diets free from known food allergens to that they

were sensitive. The primary indicators used to evaluate the formula according to the invention were weight, height, intake, stool patterns, blood biochemistry (complete blood count, serum albumin, ferritin, transthyretin, retinol binding protein, retinol and urea nitrogen, and plasma amino acids), and stool occult blood assessment. Secondary variables included gastrointestinal symptoms.

5 The non-randomized feeding study was conducted with fourteen (14) children with protein sensitive eosinophilic gastroenteritis or multiple food protein sensitivity. Each child served as his/her own control. All subjects prior to admission to the study were subjected to a double blind, placebo-controlled food challenges with the child's current formula and the inventive composition to determine if it elicited any allergic symptoms. Previous medical records, growth history for up to the
10 past twelve (12) months, detailed medical and dietary histories and records of oral challenge results for each subject were obtained.

 The elemental product produced in Example 1 was provided as a powder in 350 g cans and was reconstituted to meet the individualized needs of each child as determined by the research dietitian. The inventive formula was flavored with approved flavorings determined by the
15 investigator. Children were allowed to ingest only those foods that could be tolerated, the study formula and flavorings approved by the investigator.

 On Day 1 of the study, blood and stool samples were collected and subjects were again assessed at one (1) and four (4) month post-start dates for growth, formula intake, tolerance and blood and stool parameters (4 months only).

20 Subjects were removed from the study on the basis of a protocol failure or a treatment failure. A child was considered a protocol failure if he or she failed to comply with scheduled examination, was voluntarily removed by the parent, failed to consume sufficient amounts of the study formula or removed by the physician because he or she believed it was in the child's best interest. Children were considered a treatment failure if they were unable to consume the study
25 formula due to intolerance or an allergic reaction to the study formula.

 Careful measurements of weight, height and head circumference were made upon enrollment into the study, at each visit and at study exit using standard techniques and equipment. Available weight and height data collected during the one-year period prior to the start of the study were used for historical comparisons.

30 At the four-month point, the elemental product produced in Example I was supplying an average of 58% of total calories per day for the children, with the remainder being supplied by authorized (i.e., tolerized foods) foods. In general, the children maintained growth while on the study

formula. Only one subject experienced a slight decrease in rate of growth while consuming the study formula and this may have been caused by problems at home (parental separation).

The children in the study often had little appetite for solid foods and weight gains would have improved if energy intakes were increased to meet the recommended RDA. Hemoglobin and
5 hematocrit concentrations in study subjects were significantly improved during the study period. Other blood chemistries assessed were generally maintained at levels similar to those at entrance. Insufficient data were available at the time of filing this application to assess the effect of the study formula on serum vitamins. Data is continuing to be collected in this study and will be statistically analyzed.

10 Stool patterns improved slightly during the study period; in fact, two children were able to be toilet trained after going on the study formula due to improvement in their stools compared to their previous feeding.

In conclusion, the preliminary results of the study support the formula according to the invention is a hypoallergenic formula suitable for use in the management of children with multiple
15 food allergies or allergic eosinophilic gastroenteritis. Children grew acceptably on the inventive product when it provided the majority of the energy needs. The children tolerated the study product well and found its taste acceptable. Anecdotal comments from parents and site personnel have been positive. Data continue to be collected and statistical analysis will be conducted at the conclusion of data collection.

20 EXAMPLE 3

The hypoallergenic formula in accordance with this invention was analyzed for protein efficiency ratio (PER), that is a measure of protein quality using laboratory rats. PER is determined by dividing the animals weight gain by protein intake. Two groups of ten rats each, were fed a diet for 28 days of the hypoallergenic formula and a casein based formula using AOAC method-960.48,
25 *AOAC Official Methods of Analysis*, 15th Edition, 1990. Every seven days, the rats were weighed and their food consumption was recorded. At the end of 28 days, the total weight gain and protein composition of the two groups were calculated. These values were used to calculate the PER.

The results of this rat bioassay, set forth in Table VIII, indicate that the pediatric elemental diet, in accordance with the present invention has a significantly greater protein efficiency ratio than
30 the conventional casein based formula.

TABLE VIII

CASEIN COMPOSITION								PEDIATRIC ELEMENTAL							
Body Weights - Grams								Body Weights - Grams							
Animal	Week	Week	Week	Week	Week	Wt.		Animal	Week	Week	Week	Week	Week	Wt.	
5 No.	0	1	2	3	4	Gain		No.	0	1	2	3	4	Gain	
	1	76	86	124	158	199	123		1	71	96	133	184	237	166
	2	71	88	130	170	199	128		2	70	93	133	179	245	175
	3	72	90	122	150	190	118		3	81	99	137	187	237	156
10	4	72	86	133	159	201	129		4	75	97	145	207	266	191
	5	82	94	123	153	191	109		5	76	97	133	174	212	136
	6	79	107	150	192	232	153		6	67	95	133	187	236	169
	7	75	91	125	159	212	137		7	84	111	167	232	293	209
	8	78	89	127	158	195	117		8	80	103	144	200	247	167
15	9	68	85	119	149	197	129		9	73	100	146	190	233	160
	10	74	96	129	163	197	123		10	74	96	145	183	231	157
	Mean	75	91	128	161	201	127		Mean	75	99	141	192	244	169
	SD	4.19	6.52	8.73	12.57	12.27	12.05		SD	5.3	5.08	10.72	17.19	22.11	20.14

20

CASEIN COMPOSITION									PEDIATRIC ELEMENTAL							
Feed Consumption - Grams									Feed Consumption - Grams							
Animal	Week	Week	Week	Week					Animal	Week	Week	Week	Week			
25	No.	1	2	3	4	Total	Protein	PER	No.	1	2	3	4	Total	Protein	PER
30	1	62	102	116	133	412	42	2.92	1	81	101	134	144	460	45	3.69
	2	78	120	149	133	479	48.9	2.62	2	80	105	129	157	472	46.3	3.78
	3	71	94	110	123	399	40.7	2.89	3	79	109	139	166	492	48.2	3.23
	4	62	113	114	139	428	43.7	2.96	4	79	115	150	158	502	49.2	3.89
	5	73	95	104	128	399	40.7	2.67	5	77	97	122	144	439	43.1	3.16
	6	90	118	133	138	479	48.8	3.12	6	80	106	137	143	466	45.6	3.70
	7	75	104	121	138	438	44.7	3.06	7	90	136	163	162	551	54	3.87
	8	62	110	115	133	421	42.9	2.73	8	86	110	146	147	489	48	3.48
35	9	67	90	109	130	396	40.4	3.2	9	90	121	131	129	471	46.1	3.46
	10	85	98	124	125	432	44.1	2.79	10	80	113	124	134	450	44.1	3.56
	Mean	73	104	119	132	428	43.7	2.9	Mean	82.1	111	137	148	479	46.9	3.58
	SD	9.74	10.39	13.23	5.52	30.4	3.1	0.195	SD	4.67	11.1	12.6	12.23	31.74	3.11	0.253

EXAMPLE 4

Immunogenicity

This experiment was conducted to evaluate the allergenic potential of the elemental medical food of this invention (produced in Example 1) compared to three commercially available hypoallergenic nutritionals. Low immunogenicity demonstrated in this experiment is highly predictive of very low allergenic activity of a nutritional product.

The three commercially available products were Neocate®, Neocate® One + and Vivonex® Pediatric. In this experiment, rabbits were hyperimmunized with the nutritional according to this invention or the aforementioned commercial products using a vigorous immunization protocol employing Complete Freund's Adjuvant (CFA) with multiple injections. Enzyme-linked immunosorbent assay (ELISA) was used to measure the systemic (IgG) antigen-specific immune response of the rabbits and to define the relative immunogenicity of each product. A more detailed understanding of immunogenicity evaluation of proteins can be obtained from a review of the following articles:

- 1) Cordle, et al., "Immunogenicity Evaluation of Protein Hydrolysates for Hypoallergenic Infant Formula", J. of Ped. Gastro. and Nut., 13:270-276 (1991)
- 2) Cordle, "Control of Food Allergies Using Protein Hydrolysates", Food Technology, Oct. 1994; and
- 3) Cordle, et al., "Evaluation of the immunogenicity of protein hydrolysate formulas using laboratory animal hyperimmunization", Pediatr. Allergy Immunol, 5:14-19, (1994).

The teachings of the three listed articles are incorporated herein by reference.

Samples of each product were mixed with sterile phosphate buffered saline (PBS) to result in a concentration of 5 mg protein (amino acids) per 1.5 ml (PBS solution). The primary immunization was prepared by emulsifying 1.5 ml of the PBS product solution with 3.0 ml of CFA. The booster immunization was prepared by mixing 1.5 ml of each PBS solution with 1.5 ml of CFA. These samples were then administered at a dose of 5 mg protein equivalent per each of two immunizations.

The animals were placed on a vegetable diet (milk, soy and rice free) for 14 days prior to the primary immunization and remained on this diet for the duration of the study. Pre-immunization blood samples were taken from each rabbit on day 0, and then each rabbit was immunized. On day 21, a second immunization was conducted. The animals were exsanguinated on day 35. Serum was collected and stored at -20°C until testing.

Antibody responses were quantitated by an ELISA developed for each antigen as follows. ELISA plates were coated with the immunizing formula at an optimal (saturating) concentration. The plates were blocked with PBS containing 0.05% egg albumin and 0.1% Tween 20 to eliminate non-specific binding. Test antisera were serially diluted and added to the coated plates. Next
 5 goat anti-rabbit IgG horseradish peroxidase conjugate was added to react with any rabbit antibody bound to the immunogen. Addition of the enzyme substrate (tetramethylbenzidine) caused a color change that was directly proportional to the amount of antibody bound. Antibody titer was defined as the reciprocal of the dilution of serum that gave an ELISA optical density of 0.3 at 450 nm 10 minutes after the enzyme substrate addition.

10 Five (5) rabbits were immunized with each nutritional product. The data contained in Table IX sets forth the mean titer for each group of five rabbits and the standard deviations on day 0 and day 35.

TABLE IX

15	FORMULA	DAY	MEAN TITER	SD
	Ex. 1	0	21	12
		35	119*	83
	Neocate	0	92	24
		35	389*	222
20	Neocate One +	0	351	111
		35	56,000	27,505
	Vivonex Pediatric	0	304	185
		35	646*	469

25 SD = standard deviation
 * = not significantly different

While the titers for the formula according to this invention were actually lower than all of the commercial products, it can only be concluded that the elemental formula produced in Ex. 1 was far superior to Neocate One +. It can also be concluded that the formula according to the
 30 invention demonstrates very low immunogenicity, indicating that the product according to the invention will demonstrate clinical hypoallergenic performance. Further, these data support the use of the instant invention for people that are exquisitely sensitive to milk proteins or that react to extensively hydrolyzed protein formulas.

EXAMPLE 5

Organoleptic Test

One important aspect of this invention resides in the taste of the formula made in accordance with the invention. Most elemental medical foods presently available have a highly unpleasant taste and, as such, patients using these formulas are less likely to consume the necessary Caloric intake or may even be non-compliant with therapy.

The elemental medical food produced in Example 1 was taste tested against four commercially available formulas. The product name and sample number for each product evaluated is set forth in Table X.

10

TABLE X

SAMPLE	COMMERCIAL NAME	SUPPLIER
Ex. 1	Present Invention	Abbott Laboratories
A	Vivonex Pediatric	Sandoz Nutrition Co.
B	Neocate	SHS
C	Neocate One +	SHS
D	Elemental 028	SHS

15

All samples were supplied as unflavored powders and were reconstituted with water as shown in Table XI.

20

TABLE XI

SAMPLE	WT. OF POWDER	WT. OF WATER
Ex. 1	354 g	1301 g
A	194 g	594 g
B	342 g	1420 g
C	100 g	340 g
D	200 g	674 g

25

Fifty-one (51) volunteers were recruited to evaluate the relative acceptability of a formula according to this invention compared to the 4 commercially available elemental medical foods.

The procedure for this organoleptic evaluation consisted of providing a sample of the inventive formula to each evaluator, having them taste it and then comparing the taste of the 4 commercial formulas to the taste of the inventive formula. Each sample was evaluated at 24°C and evaluated with the following scale:

- | | |
|---|---------------------------------|
| 9 = Extremely better than Ex. 1 | 4 = Slightly worse than Ex. 1 |
| 8 = Very much better than Ex. 1 | 3 = Moderately worse than Ex. 1 |
| 7 = Moderately better than Ex. 1 | 2 = Very much worse than Ex. 1 |
| 6 = Slightly better than Ex. 1 | 1 = Extremely worse than Ex. 1 |
| 5 = Neither better nor worse than Ex. 1 | |

35

The raw data from each evaluator was collected. Means, standard deviations and p-values were calculated. Significance was determined at the 95% Confidence Level, Turkey Criteria. Comparison of Ex. 1 was considered significant if the p-value was < 0.0125 , using Bonferroni Criteria. The results of this organoleptic test are set forth in Table XII.

5

TABLE XII

	SAMPLE	MEAN	STATISTICAL GROUP	P< or >5
	A	2.63	C	0.0000
10	B	4.16	B	0.0000
	C	5.08	A	0.6623
	D	5.06	A	0.7433

Samples that share a letter under the heading Statistical Group are not significantly different. From the data presented in Table IX, it is evident that commercial products A and B were significantly worse than Ex. 1. Therefore, the formula according to this invention provides an elemental medical food that possesses highly acceptable flavor.

Industrial Applicability

This invention provides a palatable, hypoallergenic/elemental product for the nutritional maintenance of humans that suffer from protein allergies. The medical community is constantly in search of improved formulations for their patients that supply a complete diet in a pleasant tasting matrix. As demonstrated in the examples, the formula in accordance with the present invention is easily manufactured and provides acceptable growth and tolerance to patients consuming same.

The embodiments of the present invention may, of course, be carried out in other specific ways than those set forth herein without departing from the spirit and essential characteristics of the invention. The present embodiments are therefore, to be considered in all respects as illustrated and not restrictive.

We claim:

1. An elemental medical food for administration to a human comprising:
 - a) a carbohydrate component which comprises from 38 to 56% of the total Caloric content of said food;
 - b) a lipid component which comprises from 38 to 50% of the total Caloric content of said food and wherein said lipid component is a blend of high-oleic safflower oil, fractionated coconut oil, esterified glycerols and soy oil; and
 - c) an amino acid component which comprises from 10 to 20% of the total Caloric content of said food and wherein said amino acid component is essentially free of L-glutamic acid and L-aspartic acid.
2. The elemental medical food according to claim 1 wherein said carbohydrate component comprises from 38 to 56% of the total Caloric content of said food and wherein said lipid component comprises from 38 to 50% of the total Caloric content of said food and wherein said amino acid component comprises from 10 to 20% of the total Caloric content of said food.
3. The elemental medical food according to claim 1 wherein said amino acid component comprises: 2.3 to 3.2 wt % - L-histidine; 5.9 to 8.5 wt % - L-isoleucine; 9.5 to 14.0 wt % - L-leucine; 6.6 to 9.7 wt % - L-valine; 5.2 to 7.6 wt % - L-lysine; 2.2 to 3.2 wt % - L-methionine; 4.9 to 7.1 wt % - L-phenylalanine; 3.8 to 5.7 wt % - L-threonine; 1.4 to 2.2 wt % - L-tryptophan; 3.0 to 4.2 wt % - L-alanine; 5.3 to 7.7 wt % - L-arginine; 8.6 to 12.4% L-asparagine monohydrate; 1.1 to 1.9% - L-cystine dihydrochloride; 11.0 to 15.8 wt % - L-glutamine; 2.3 to 3.2 wt % - glycine; 3.0 to 4.1 wt % L-proline; 3.0 to 4.2 wt % - L-serine; and 5.0 to 7.1 wt % - L-tyrosine.
4. The elemental medical food according to claim 1 wherein said carbohydrate component consists essentially of corn syrup solids with a DE of 23 or less.
5. The elemental medical food according to claim 1 in powder form.
6. The elemental medical food according to claim 1 wherein about 4 grams of said composition is added to water to make about 30 ml and has an osmolality of 300 to 400 mOsm/kg H₂O.
7. The elemental medical food according to claim 1 wherein said lipid component comprises 37 to 41% high oleic safflower oil; 28 to 35% fractionated coconut oil; 24 to 30% soy oil and 0.5 to 8% esterified glycerols based on the total weight of said lipid component.

8. The elemental medical food according to claim 1 which additionally comprises at least one element selected from the group consisting of nucleosides, nucleotides, antioxidant system, natural flavor, artificial flavors, artificial sweeteners, major trace and ultratrace minerals, minerals, vitamins and m-inositol.
9. The elemental medical food according to claim 6 wherein said composition has a Caloric density of about 0.68 kcalories/ml and an osmolality of 350 to 375 mOsm/kg H₂O.
10. The elemental medical food according to claim 1 comprising, based on 100 kcalories of said composition: 2.8 to 3.8 g protein equivalent; 4.0 to 5.6 g fat, 9.0 to 11.8 g carbohydrate; 0.4 to 0.8 g linoleic acid; 262 to 475 IU Vitamin A; 40 to 80 IU Vitamin D; 2.0 to 3.5 IU Vitamin E; 5 to 20 mcg Vitamin K; 0.11 to 0.42 mg thiamine, 0.1 to 0.21 mg riboflavin; 0.09 to 0.17 mg Vitamin B-6; 0.40 to 1.36 mcg Vitamin B-12; 1.6 to 3.2 mg niacin; 28 to 60 mcg folic acid; 0.40 to 1.70 mg pantothenic acid; 4.0 to 18.0 mcg biotin; 8.6 to 85 mg Vitamin C; 7.5 to 14.6 mg choline; 4.6 to 9.9 mg inositol; 4.0 to 6.5 mg L-carnitine; 103 to 127 mg calcium; 76 to 103 mg phosphorus; 8.0 to 12.7 mg magnesium; 1.6 to 2.4 mg iron; 1.0 to 1.7 mg zinc; 0.10 to 0.15 mg manganese; 0.11 to 0.19 mg copper; 6.7 to 11.8 mcg iodine; 2.2 to 4.7 mcg selenium; 2.2 to 4.7 mcg chromium; 2.4 to 5.5 mcg molybdenum; 40 to 55 mg sodium; 144 to 174 mg potassium and 55 to 85 mg chloride.
11. The elemental medical food according to claim 5 comprising, based on 100 grams of powder: 14.3 g protein equivalent; 22.6 g lipid; 46.7 g carbohydrate; 2.85 g linoleic acid; 0.48 g α -linolenic acid; 515 mg calcium; 385 mg phosphorus; 390 mcg Vitamin A; 5 mcg Vitamin D; 6.7 mg Vitamin E; 30 mcg Vitamin K; 1.0 mg thiamine, 0.50 mg riboflavin; 0.48 mg Vitamin B-6; 2.0 mcg Vitamin B-12; 8.0 mg niacin; 140 mcg folic acid; 2.0 mg pantothenic acid; 20 mcg biotin; 43 mg Vitamin C; 38 mg choline; 24 mg inositol; 23 mg L-carnitine; 40 mg magnesium; 8.4 mg iron; 5.3 mg zinc; 0.50 mg manganese; 0.60 mg copper; 34 mcg iodine; 11 mcg selenium; 11 mcg chromium; 12 mcg molybdenum; 9.35 mEq sodium; 18.29 mEq potassium and 8.04 mEq chloride.
12. The elemental medical food according to claim 1 wherein said carbohydrate component is corn syrup solids with a DE of 23 or less; said lipid component comprises 35 to 41% by wt high oleic safflower oil, 28 to 35% by wt fractionated coconut oil, 24 to 30% by wt soy oil and 0.5 to 8% by wt of diacetyl tartaric acid esters of monoglycerides; and said amino acid component comprises L-asparagine monohydrate and L-glutamine.

13. A method for providing nutrition support to a human suffering from food protein allergens, said method comprises the enteral administration of an elemental medical food comprising:
- a carbohydrate component which comprises from 38 to 56% of the total Caloric content of said food;
 - a lipid component which comprises from 38 to 50% of the total Caloric content of said food and wherein said lipid component is a blend of high-oleic safflower oil, fractionated coconut oil, soy oil and esterified glycerols; and
 - an amino acid component which comprises from 10 to 20% of the total Caloric content of said food and wherein said amino acid component is essentially free of L-glutamic acid and L-aspartic acid.
14. The method according to claim 13 wherein the gastrointestinal condition is selected from the group consisting of eosinophilic gastroenteritis, short gut syndrome, gastroenteritis, inflammatory bowel disease, intractable diarrhea and gastroesophageal reflux.
15. The method according to claim 13 wherein the elemental medical food comprises, based on 100 kcal of said composition: 2.8 to 3.8 g protein equivalent; 4.0 to 5.6 g fat, 9.0 to 11.8 g carbohydrate; 0.4 to 0.8 g linoleic acid; 262 to 475 IU Vitamin A; 40 to 80 IU Vitamin D; 2.0 to 3.5 IU Vitamin E; 5 to 20 mcg Vitamin K; 0.11 to 0.42 mg thiamine, 0.1 to 0.21 mg riboflavin; 0.09 to 0.17 mg Vitamin B-6; 0.40 to 1.36 mcg Vitamin B-12; 1.6 to 3.2 mg niacin; 28 to 60 mcg folic acid; 0.40 to 1.70 mg pantothenic acid; 4.0 to 18.0 mcg biotin; 8.6. to 85 mg Vitamin C; 7.5 to 14.6 mg choline; 4.6 to 9.9 mg inositol; 4.0 to 6.5 mg L-carnitine; 103 to 127 mg calcium; 76 to 103 mg phosphorus; 8.0 to 12.7 mg magnesium; 1.6 to 2.4 mg iron; 1.0 to 1.7 mg zinc; 0.10 to 0.15 mg manganese; 0.11 to 0.19 mg copper; 6.7 to 11.8 mcg iodine; 2.2 to 4.7 mcg selenium; 2.2 to 4.7 mcg chromium; 2.4 to 5.5 mcg molybdenum; 40 to 55 mg sodium; 144 to 174 mg potassium and 55 to 85 mg chloride.
16. A method for the nutrition support of a human suffering from a malady selected from the group consisting of severe food allergies, short gut syndrome, cystic fibrosis, pancreatic disease, gastroenteritis, inflammatory bowel disease, intractable diarrhea, malnutrition, protein maldigestion, necrotizing enterocolitis, infectious diseases, hypermetabolism, trauma, eosinophilic gastroenteritis and gastroesophageal reflux; said method comprising the administration to said human of a formula comprising:
- a carbohydrate component which comprises from 38 to 56% of the total Caloric content of said food;

- b) a lipid component which comprises from 38 to 50% of the total Caloric content of said food and wherein said lipid component is a blend of high-oleic safflower oil, fractionated coconut oil, esterified glycerols and soy oil; and
 - c) an amino acid component which comprises from 10 to 20% of the total Caloric content of said food and wherein said amino acid component is essentially free of L-glutamic acid and L-aspartic acid.
17. A hypoallergenic medical food comprising:
- a) a carbohydrate component which comprises from 38 to 56% of the total Caloric content of said food;
 - b) a lipid component which comprises from 38 to 50% of the total Caloric content of said food and wherein said lipid component is a blend of high-oleic safflower oil, fractionated coconut oil, esterified glycerols and soy oil; and
 - c) an amino acid component which comprises from 10 to 20% of the total Caloric content of said food and wherein said amino acid component is essentially free of L-glutamic acid and L-aspartic acid.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/11986

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A23L1/29

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 705 542 A (SANDOZ NUTRITION) 10 April 1996 see page 2, line 40 - page 3, line 4; claims ---	1-17
A	EP 0 560 989 A (OTSUKA PHARMACEUTICAL) 22 September 1993 see page 4, line 38 - page 5, line 3 ---	1-17
A	US 5 411 757 A (N.R.BUIST ET AL.) 2 May 1995 cited in the application see claims ---	1-17
A	US 5 340 603 A (M.J.NEYLAN ET AL.) 23 August 1994 cited in the application see claims; tables 10,11 ---	1-7
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 November 1998

Date of mailing of the international search report

03/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Moer, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/11986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 326 569 A (P.J.B.ACOSTA ET AL.) 5 July 1994 cited in the application see claims -----	1-17
A	US 5 550 146 A (P.J.B.ACOSTA ET AL.) 27 August 1996 cited in the application see claims -----	1

INTERNATIONAL SEARCH REPORT

In. ational application No.

PCT/US 98/ 11986

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/11986

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 705542	A	10-04-1996	US 5719133 A	17-02-1998
			AT 161397 T	15-01-1998
			CA 2158635 A,C	22-03-1996
			DE 69501306 D	05-02-1998
			DE 69501306 T	18-06-1998
			ES 2111384 T	01-03-1998
			GR 3026072 T	29-05-1998
			SG 33502 A	18-10-1996
			SI 705542 T	30-04-1998
			US 5719134 A	17-02-1998
EP 560989	A	22-09-1993	AU 651738 B	28-07-1994
			AU 2691392 A	03-05-1993
			CA 2097196 A	08-04-1993
			WO 9306834 A	15-04-1993
			JP 2743119 B	22-04-1998
			MX 9205722 A	01-11-1993
			US 5658895 A	19-08-1997
US 5411757	A	02-05-1995	NONE	
US 5340603	A	23-08-1994	NONE	
US 5326569	A	05-07-1994	AU 669252 B	30-05-1996
			AU 5599294 A	19-07-1994
			CA 2143418 A	07-07-1994
			EP 0675689 A	11-10-1995
			WO 9414341 A	07-07-1994
US 5550146	A	27-08-1996	US 5587399 A	24-12-1996
			AU 679020 B	19-06-1997
			AU 5599194 A	19-07-1994
			CA 2143420 A	07-07-1994
			EP 0675725 A	11-10-1995
			WO 9414458 A	07-07-1996